According to NBD AI News, on November 13th, Leadman...(300289.SZ) disclosed a draft report on a major asset purchase, proposing to acquire 70% of the shares of Xiansheng Xiangrui from Shanghai Baijiahui Investment Management Co., Ltd., Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership), and Hainan Xiansheng Baijiahui Technology Development Co., Ltd. for RMB 1.733 billion in cash. The target company is mainly engaged in biological products.(In vivo diagnostic reagents, vaccines) and in vitro diagnosticsThe company focuses on the research, development, production, and sales of reagents, with its core products being TB-PPD, BCG-PPD, and IGRA, all concentrated in the field of tuberculosis screening and diagnosis. On the other hand, Simcere is one of the few companies in China holding a vaccine production license, focusing on innovative human vaccines that do not yet meet clinical needs. Simcere's Xs03 project, applied to the field of meningitis, has submitted a pre-IND application, and several other innovative projects are in the preclinical stage. By acquiring a controlling stake in the target company, the company can quickly enter the biopharmaceutical industry, which has high barriers to entry and a broader market prospect.

https://finance.eastmoney.com/a/202511133563714528.html